1 / 6

Discover the Idiopathic Pulmonary Fibrosis (IPF) Pipeline Exhibits Strong Pipeline With 95 Drug Candidates

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.

NidhiNehani
Download Presentation

Discover the Idiopathic Pulmonary Fibrosis (IPF) Pipeline Exhibits Strong Pipeline With 95 Drug Candidates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Idiopathic Pulmonary Fibrosis (IPF) Pipeline to Witness Huge R&D Investment in the Coming Years

  2. Idiopathic Pulmonary Fibrosis (IPF) According to a new research report “Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, the IPF exhibits strong pipeline with estimated 104 drug candidates in 2017. Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

  3. Idiopathic Pulmonary Fibrosis (IPF) Insights on pipeline segments As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.

  4. Idiopathic Pulmonary Fibrosis (IPF) More than 10 drug candidates received Orphan Drug Designation (ODD) The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

  5. Idiopathic Pulmonary Fibrosis (IPF) Download report sample at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related